Breast cancer is one of the most common types of malignancy, with an increasing incidence worldwide. Breast cancers are subtyped based on their histopathological features and hormonal receptor expression status. Conventional radiological modalities such as mammography, ultrasonography, computed tomography, and magnetic resonance imaging play a major role in the diagnosis and initial staging of breast cancer. Positron emission tomography with F-18-fluorodeoxyglucose (FDG) has an established role in the staging of locally advanced breast cancers, along with its use in response assessment after systemic therapy. Non-FDG radiopharmaceuticals also have a potential role in breast cancer imaging. These include agents that target hormonal and tyrosine kinase receptors, tumor microenvironment, and fibroblast activation protein inhibitors. Gamma camera-based modalities such as breast-specific gamma imaging, sentinel lymph node imaging, and skeletal scintigraphy also play a significant role in the management of subsets of patients with breast malignancy.
Copyright: The Authors.; The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holder(s), and all original sources have been appropriately acknowledged or referenced. Where relevant, informed consent has been obtained from patients or their caregivers according to applicable national or institutional policies.